J&J’s Biotech Strategy: Balancing Bargain Hunting with Innovation Needs
Strategic Shifts in Pharmaceutical Acquisition Johnson & Johnson, the world’s largest healthcare company, has successfully leveraged a low-cost partnership model to build its oncology portfolio over the past decade. By prioritizing early-stage collaborations and licensing agreements over massive, high-risk acquisitions, the New Brunswick-based pharmaceutical giant has secured significant market share in cancer treatment while avoiding…